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ABSTRACT
The Fip1-like1 (FIP1L1)–platelet-derived growth factor receptor alpha (PDGFRA) 
(F/P) oncogene can cause chronic eosinophilic leukemia (CEL), but requires IL-5 
cytokine participation. In this study, we investigate the mechanism of F/P in 
collaboration with IL-5 in CEL. The results showed that Lyn, a key effector in the 
IL-5-motivated eosinophil production, is extensively activated in F/P-positive CEL 
cells. Lyn can associate and phosphorylate IL-5 receptor α (IL-5RA) in F/P-positive 
cells. Moreover, the activation of Lyn and IL-5R kinase were strengthened when the 
cells were stimulated by IL-5. Lyn inhibition in F/P-positive CEL cells attenuated 
cellular proliferation, induced apoptosis, and blocked cell migration and major basic 
protein (MBP) release. We identified the FIP1L1-PDGFRA/JAK2/Lyn/Akt complex in 
the F/P-expressing cells which can be disrupted by dual inhibition of JAK2 and Lyn, 
repressing cell proliferation in both EOL-1(F/P-positive human eosinophilic cell line) 
and imatinib-resistance (IR) cells. Altogether, our data demonstrate that Lyn is a 
vital downstream kinase activated by F/P converged with IL-5 signals in CEL cells. 
Lyn activate and expand IL-5RA intracellular signaling through FIP1L1-PDGFRA/
JAK2/Lyn/Akt network complex, provoking eosinophils proliferation and exaggerated 
activation manifested as CEL. 
INTRODUCTION
Hypereosinophilic syndrome (HES) is defined as 
an unexplained persistent eosinophilia exceeding 1500/
mm3 eosinophils per liter for more than 6 months in 
combination with symptoms and signs of organ damage 
resulting from eosinophil infiltration. It includes different 
types of hematologic diseases with male predominance and 
age distribution of 20–50 year-old. The FIP1L1-PDGFRA 
fusion gene(F/P) induces constitutive PDGFRA kinase 
activation, and exists in about 10–20% of HES/CEL [1]. 
F/P-positive HES/CEL patients present with exaggerated 
eosinophils proliferation and thus end-organs impairment 
due to eosinophil invasion and granulation toxicity 
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[1, 2]. As a driver oncogene, F/P induces eosinophil 
abnormal differentiation and clonal proliferation in 
vitro. Nevertheless, simple expression of F/P into 
mice bone marrow cells results in the generation of a 
myeloproliferative disease without striking eosinophilia 
[3]. Introduction of interleukin-5 (IL-5) was necessary to 
recapitulate typical features of HES/CEL, including hyper 
eosinophilia and tissue infiltration of eosinophils when co-
expressed with F/P fusion gene [4]. But the underlying 
mechanism was not yet fully understood.
IL-5 is a critical factor for eosinophil production and 
activation, but animal model showed that CD2-IL-5 Tg 
induced eosinophilia in blood, not in tissue [5]. Recently, 
some reported that amplification of IL-5 signaling by F/P 
triggers a CEL-like disease [6, 7]. Likewise, IL-5 can 
enhance blood eosinophil responsiveness to a second 
stimulus or event, resulting in a synergistic response, 
which was a radical mechanism of severe eosinophil-
related inflammation. The process of cooperation between 
IL-5 and second stimulus did focus on the changes 
in intracellular signaling events [8]. Therefore, we 
hypothesized that preferential eosinophil development and 
overacting eosinophils, as a causal role of tissue eosinophil 
infiltration in F/P-positive CEL, maybe correlated with the 
synergistic effects of IL-5 with the F/P oncoprotein. 
The IL-5 receptor A (IL-5RA) subunit is very 
important for IL-5 pathway and eosinophil development 
[9]. Lyn is physically associated with the IL-5RA chain 
upon receptor ligation, which appears critical for the 
subsequent activation of downstream signal pathway [10]. 
Autoinhibitory WW-domain of PDGFRA 
gene disrupted by the fusion of FIP1L1 translated 
the constructive activation kinase of PDFGRA into 
intracellular signal cascade [11]. The activated 
PDGFRA can bind and activate the signal molecules 
consisting of SH2-domain in cytoplasm [12]. Lyn is a 
member of Src family and characteristic of SH2 domain 
in addition to the kinase domain, and it stimulates 
PDGFR-induced malignant hematopoiesis [13]. Some 
reports about the downregulation of phosphorylated Lyn 
with EOL-1 (F/P-positive human eosinophilic cell line) 
cell growth inhibition in dasatinib treatment indicate 
that Lyn is the downstream of F/P oncoprotein [14]. But 
it was still unknown whether Lyn was involved in F/P-
induced CEL.
First, we tested the idea if Lyn kinase was engaged 
in F/P signal-triggered CEL malignant phenotype, 
and whether Lyn activation in F/P-positive cell was 
strengthened by IL-5 cytokine. Then, we investigated 
whether Lyn can bind with Janus kinase 2 (JAK2) in F/P-
spurring signal cascade [15]. Finally, we explored if Lyn 
kinase was in the F/P signal propagation, leading to the 
facilitation of IL-5RA intracellular signal pathway. 
The results indicate that Lyn is a key downstream of 
F/P oncoprotein, which is responsible for F/P-stimulated 
eosinophils proliferation and apoptosis retardance. 
Moreover, the Lyn kinase serves as a critical component for 
imposing F/P-stirred eosinophil activation and major basic 
protein (MBP) release in response to IL-5 stimulation. 
Lyn can induce tyrosine phosphorylation of IL-5RA in 
F/P-expressing cells, and then facilitate the IL-5RA signal 
pathway to promote reinforced eosinophils function. 
The complex of F/P/JAK2/Lyn/Akt was identified in the 
F/P-expressing cells, and its disruption with combined 
inhibition of JAK2 and Lyn led to a dramatic depression 
of cell proliferation. These results also provide a potential 
alternative therapy for F/P-positive CEL.
RESULTS
Excessive phosphorylation of Lyn in F/P-positive 
CEL patients 
We explored if Lyn was excessively activated in 
the F/P-induced CEL. The study included twenty-three 
HES cases. Polymorph nuclear leucocytes, as well as 
eosinophils were gathered for the immunoblotting [15]. 
The results displayed that the level of phospho-Lyn in 
F/P-positive [F/P(+)] CEL were higher than that in other 
eosinophilia cases without F/P gene (Figure 1). 
Lyn activation was inhibited with imatinib 
treatment in F/P(+) CEL patients and EOL-1 
cells 
Imatinib therapy is effective in F/P-positive cells 
and is the first choice for initial treatment in F/P(+) 
CEL patients. The patients with F/P gene were initially 
prescribed imatinib, and molecular remission was achieved 
in about 3–12 months after imatinib intervention. Proteins 
were extracted from the peripheral blood samples which 
were collected at four different time-points: day 0 (pre-
therapy), day10 and day 30 of post-therapy, and the day of 
molecular remission (M.R.) [15]. At the same time, EOL-
1 cells were treated with different doses of imatinib. The 
results demonstrated that phospho-Lyn level was gradually 
reduced in the F/P(+) CEL cases and EOL-1 cells with 
phospho-F/P inhibited by imatinib (Figure 1), which 
suggested Lyn kinase is the target of F/P oncoprotein.
Lyn inhibition suppresses colony formation, 
induces apoptosis and prevents migration in 
response to IL-5 in F/P-positive CEL cells 
To determine whether Lyn promotes cell 
proliferation, inhibits cell apoptosis and stimulates 
migration of F/P-positive CEL cells, we inhibited or 
knocked down Lyn with specific inhibitor PP2 or Lyn 
siRNA, and then assessed the clone-forming, cell apoptosis 
and migration. The results showed that colony formation 
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was gradually inhibited with increasing dose of Lyn 
inhibitor, as well with Lyn knockdown in EOL-1 cells 
(Figure 2). The clone-forming of PC and IR cells were also 
dramatically inhibited after Lyn inhibition or knockdown 
(Figure 2). Lyn inhibition or knockdown in EOL-1 cells 
led to obvious cell apoptosis or even death. Similarly, PC 
or IR cells were also very sensitive to Lyn inhibition or 
knockdown (Figure 2 and Supplementary Figure S2). To 
explore whether Lyn stimulates migration of F/P-positive 
cells, IL-5 cytokine was used as chemoattractant in these 
cells. The cell migrations were suppressed when Lyn 
was inhibited by PP2 or knockdown with special Lyn 
siRNA (Supplementary Figure S3). Taken together, these 
observations suggest that proliferation, survival, and 
migration in F/P-positive cells maybe depend on cellular 
Lyn kinase activity, and Lyn molecule can be an alternative 
feasible treatment target for imatinib-resistant CEL. 
Notably, the level of phospho-Jak2 was not decreased by 
Lyn inhibition (Supplementary Figure S4), which indicated 
that JAK2 was not downstream of Lyn.
IL-5 stimulation reinforced F/P-induced lyn 
activation 
IL-5 cytokine is necessary for developing full CEL 
picture in the coordination with F/P oncoprotein. Lyn, 
as a critical mediator of IL-5 signaling pathway, was 
also proved to be activated by F/P oncoprotein in our 
previous findings. So we hypothesized that Lyn is the 
common target by F/P cooperated with IL-5 intracellular 
pathway in F/P-positive cells. To verify this hypothesis, 
we stimulated EOL-1 cells with IL-5 cytokines with or 
without 10 nM imatinib treatment. Our findings displayed 
that IL-5 stimulation dramatically increased phospho-Lyn 
Figure 1: Lyn activation in F/P(+) CEL patients and was inhibited with the reduction in phosph-F/P by imatinib 
treatment. Cell extracts were prepared from blood samples of the cases and subjected to Western blotting or immunoprecipitation (IP). 
(A, D) Reprsentative gell images. (B–C) Quantification of A. (E–F) Quantification of D. Data(mean ± SD) represent of the cases(F/P(+) 
CEL[n = 11], F/P(−) HES [n = 12], RE [n = 5], and healthy volunteers[n = 5]), or derived from three independent experiments.*P < 0.05, 
F/P(+) group compared to the other groups. F/P(+):F/P(+) CEL, F/P(−):F/P(−)HES,RE: reactive eosinophilia. #P < 0.05, compared to day 0 
or the untreated group.
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level in F/P-expressing CEL cell, which can be obviously 
suppressed by imatinib, suggesting a collaborated 
activation of Lyn by F/P and IL-5 (Figure 3).
Lyn inhibitor or knockdown suppresses IL-5-
stimulated MBP release and the activation of 
PI3K/Akt pathway
MBP is the major cytotoxic granule in eosinophil, 
which takes key responsibility for eosinophil-associated 
organ damage depending on the activation of PI3K/
Akt molecules [16]. Lyn was shown to be the focus 
downstream of cytokine IL-5 and F/P oncoprotein, and 
then we assessed whether Lyn participate the cooperation 
effect of IL-5 and F/P inducing eosinophil activation 
and PI3K/Akt activation. The results showed that Lyn 
inhibition strikingly suppressed IL-5-stimulated MBP 
release and PI3K/Akt activation in F/P-positive CEL 
cells (Figure 4). But there was no difference in the signal 
transducer and activator of transcription 5 (Stat5) or 
extracellular-regulated kinase (ERK) activation with 
or without IL-5-stimulation in F/P(+) EOL-1 cells 
(Figure 4). PI3K inhibitor GDC 0941, but not MEK 
inhibitor [PD 325901], reduced the MBP release of EOL-
1 and IR cells (Supplementary Figure S5). These findings 
indicate that excessive Lyn activation endows the 
invasive power of F/P-positive eosinophils by activating 
PI3K/Akt pathway.
Figure 2: Lyn inhibition suppressed colony formation, induced apoptosis in EOL-1,PC and IR cells. Cells were treated with 
various concentrations of PP2 or transfected with Lyn siRNA. Colony formation was assessed by soft agar colony-forming experiments, 
apoptosis assessed by flow cytometry using Annexin-V and PI. (A–C) Inhibitory rate of cells treated with various concentrations of PP2 
or transfected with Lyn siRNA. (D) Representative flow cytometry patterns. (E–G) Percentages of apoptotic cells treated with various 
concentrations of PP2 or transfected with Lyn siRNA. Data (mean ± SD) representative results derived from three independent experiments 
[EOL-1 and IR] or the seven F/P-positive CEL patients.*P < 0.05,compared to untreated group or control siRNA.
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Lyn binds to the cytoplasmic region of IL-5RA 
and induces its tyrosine phosphorylation in F/P-
expressing cells
Although animal model indicated that the crucial 
synergistic effect of IL-5 on the whole F/P-triggered CEL 
characteristics, serum IL-5 level was usually normal in F/P-
positive cases [17]. The consensus of the forgoing function 
of IL-5 is attributable to the signaling via the IL-5RA. 
F/P signal pathway sensitize IL-5R-positive myeloid 
progenitor and precursors to IL-5 stimuli, may be by a 
presumed up-regulation role on IL-5RA of F/P-expressing 
cells, imposing eosinophil production and activation 
[4]. Therefore, it is plausible that activated intercellular 
Lyn kinase can bind with IL-5RA bringing about and 
enhancing the activation of IL-5RA signaling pathway. 
The other evidence supporting our hypothesis is that Lyn 
is correlated with different transmembrane receptors, 
including IL-5R, in diverse cell categories [10, 18]. To 
address this concern, we stimulated F/P(+) EOL-1 cells 
with IL-5. A phosphorylated protein corresponding in 
size to IL-5RA was shown to be co-immunoprecipitated 
with Lyn when IL-5 cytokine was added (Figure 5A). We 
also detected that phospho-IL-5RA combination to Lyn 
protein was increasing upon the IL-5 stimulation time 
in EOL-1 cells (Figure 5B). And then, we ask if Lyn can 
stimulate the activation of IL-5R, IL-5R was co-expressed 
with F/P into CD34 (+) cells. IL-5 could not stimulate 
observable phospho-IL-5RA level when the cells were 
only introduced with IL-5RA. But F/P and IL-5RA co-
expression promoted a conspicuous activation of IL-5R 
despite the lack of IL-5 induction (Figure 5C). The level 
of tyrosine phosphorylation of the IL-5R was significantly 
enhanced by IL-5 stimulation. In vitro kinase assay was 
applied for the detection of IL-5R kinase. Compared with 
unstimulated or untransfected cells, the IL-5R tyrosine 
kinase was significantly enhanced by approximately 
273.4% or 434.3% respectively (Figure 5D–5E). The 
phosphorylated protein equivalent to the molecule weight 
of Lyn was co-immunoprecipitated with IL-5R in the cell 
co-expressing F/P and Lyn (Figure 5C). Interestingly, 
the level of phospho-Lyn protein was reinforced by IL-5 
stimulation (Figure 5C). 
Lyn is associated with FIP1L1-PDGFRA/JAK2 
signaling complex in F/P-expressing cells
Our previous study has revealed that JAK2 was 
involved in F/P-stimulated eosinophil proliferation and 
migration [15]. To identify the F/P-associated proteins, 
Figure 3: The synergistic role of F/P and IL-5 in inducing Lyn activation in EOL-1 and PC cells. The EOL-1 or PC 
cells were preincubated with or without Imatinib for 4 h followed by treatment with 5ng/mL IL-5 for 0 to 5 min. Whole-cell lysates were 
prepared and subjected to Western blotting. (A) Representative gel images. (B–C) Quantification of A. Data (mean ± SD) representative 
results derived from three independent experiments. *P < 0.05, as compared to 0 minute. #P < 0.05, compared to the differences between 
the Imatinib treatment and non-treatment for all the doses.
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detergent lysates of the mouse 32D cells and F/P(+) 32D 
cells were analyzed by immuno-precipitation with either 
F/P antibody-protein A conjugate (for F/P-associated 
proteins) or by the addition of other specific antibodies(e.g., 
JAK2, or Lyn). These same antibodies were used to 
identify F/P network-associated proteins by Western 
blotting of the immuno-precipitates. Immunoprecipitation 
and Western blotting of the detergent-soluble lysates from 
either 32D cells maintained in IL-3 or F/P(+) 32D cells 
with the anti-JAK2 antibody detected Lyn and F/P in 
the F/P(+) 32D lysate. If the same lysates were used for 
immunoprecipitation with anti-Lyn and probed with the 
respective antibodies, F/P [only in the F/P(+) 32D lysate] 
and JAK2 were detected. Immunoprecipitation with anti-
F/P of these lysates followed by Western blotting with 
the appropriated antibodies identified JAK2, and Lyn, the 
downstream effectors of F/P kinase, only in the F/P(+) 
32D lysate (Figure 6A–6C). Thus, F/P protein network 
constitutes a signaling complex, which contains JAK2, 
and Lyn. Other proteins likely to be in the F/P/JAK2/Lyn 
network should be further studied.
Identification of F/P/JAK2/Lyn/Akt complex in 
F/P-expressing cells and combined inhibition 
of the Lyn and JAK2 dramatically blocks cell 
proliferation via complex disruption
Akt hyperactivation was detected from F/P-
positive cells [19, 20]. Therefore, we hypothesized the 
possibility of F/P/JAK2/Lyn/Akt network complex in 
Figure 4: Lyn inhibition blocked IL-5-induced MBP release and the downregulation of PI3K/Akt in EOL-1 cells. 
The EOL-1 cells were treated with various concentration of PP2 or transfected with Lyn siRNA. (A) Representative gel images. (B–F) 
Quantification of A. (G) MB P values were determined using a double antibody competitive radioimmunoassay.
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the F/P-induced CEL. To address this concern, Gel 
filtration column chromatography and proteomics 
were performed [18]. Several molecules, such as Akt, 
pLyn, Lyn and JAK2 were observed in the same eluent 
(Figure 6D). Other downstream proteins, including 
pERK, pSTAT5, STAT5, should be detected in the 
further study. The complex was also detected in EOL-1 
cell (Figure 6E). When EOL-1 or IR cells were treated 
with low dose of AG490 (25 μM) and PP2 (2 μM), the 
cellular proliferation was more significantly blocked, 
compared with either AG490(25 μM ) or PP2(2 μM) 
by themselves(data not shown). Then we ask if F/P/
JAK2/Lyn/Akt network complex can be disrupted by the 
combined inhibition of JAK2 and Lyn, F/P(+) 32D cells 
were incubated with 25 μM AG490 and 2 μM PP2 for 
4 hours followed by Gel filtration column experiments. 
This broken F/P/JAK2/Lyn/Akt complex was indicated in 
Figure 6F which showed that F/P oncoprotein and the rest 
of the complex components were significantly decreased 
in quantity. These results further provide evidences that 
F/P-incited intracellular signal, center on its downstream 
of JAK2/Lyn, which then activating and recruiting the 
other downstream of F/P such as Akt, and finally leading 
to the CEL malignant traits. Moreover, disruption of the 
F/P/JAK2/Lyn/Akt complex with dual inhibitors may 
become a realistic therapeutic options for the F/P(+) CEL.
DISCUSSION
The F/P fusion gene which leads to the constitutive 
activation of PDGFRA drives the occurrence of CEL [1]. 
But the whole CEL characteristics with eosinophilia-
associated end-organ infiltration needs oncoprotein F/P 
collaborated with additional IL-5 stimulation [4, 21]. 
The mechanisms underlying the communication between 
F/P-activated molecules and IL-5-stimulated intercellular 
signal molecule were still unknown. Here, our findings 
first identified that Lyn is hyperactivated in F/P-positive 
CEL and is an important kinase in F/P-induced cell 
survival. Lyn inhibition can repress cell migration and 
Figure 5: Lyn induced tyrosine phosphorylation of IL-5RA and associated with the phospho-IL-5RA in F/P-expressing 
cells. (A) EOL-1 cells were starved overnight and left unstimulated (−) or stimulated with 5 ng/mL of IL-5 or 25 ng/mL of IL-3(IL-3) for 
5 minutes at 37°C before solubilization. Cell lysates were immunoprecipitated with anti-Lyn. Immunoprecipitates were resolved by SDS-
PAGE and subjuected to immunoblotting with an anti-phosphotyrosine monoclonal antibody, 4G10(αPY). (B) EOL-1 cells was starved 
overnightand stimulated with 5 ng/mL of IL-5 for the indicated times. Cells were then lysed and analyzed as described above. (C) In CD34+ 
cells, the IL-5R was transiently coexpressed with FIP1L1-PDGFRA as indicated. Transfected cells were either stimulated with 5 ng/mL 
of IL-5 for 5 minutes or left unstimulated, as indicated(IL-5 st. + or −, respectively).Cells were lysed and immunoprecipitated with anti-
IL-5Rα. Immunoprecipitates were analyzed by anti-phosphotyrosine(αPY) Immunoblotting followed by reprobing with anti- IL-5R, as 
indicated. A coimmunoprecipitated phosphotyrosyl protein that corresponds in size to Lyn is indicated with an asterisk. (D) Immunopurified 
IL-5R was subjected to vitro kinase assays. (E) Quantification of D.
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Figure 6: Detection of a large molecular weight signaling network complex comprised FIP1L1-PDGFRA, Jak2, Lyn 
and other proteins (e.g. Akt) in F/P-expressing cells. (A–C) Lyn and JAK2 proteins are parts of FIP1L1-PDGFRA network. F/P(+) 
32D cells were immunoprecipitated with several antibodies, and the immunoprecipitates were detected by Western blotting. (D) Proteins 
from the detergent extracted lysate of F/P/(+) 32D cells were eluted from the column by a detergent-containing buffer.From each eluant, 
a 25 μl aliquot was taken and analyzed by western blotting, and the membrane was probed with different antibodies as indicated. (E) 
Fractionation of proteins from the EOL-1 cell lysates on a gel filtration column, as described in Figure 6D. Detection of signaling molecules 
in the colum eluant was performed by western blotting. (F) Treatment of F/P(+) 32D cells with 25 μM AG490 and 2 μM PP2 for 4 hours 
disrupted the FIP1L1-PDGFRA/JAK2/Lyn network structure. The procedure for analysis was the same as used for (D). (G) Densitometric 
analysis of the Wb bands of the immunoblots of (F).
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MBP release. We further delineated that Lyn can induce 
IL-5RA tyrosine phosphorylation and physically associate 
with IL-5RA in F/P-expressing cells. Finally, the complex 
of F/P/JAK2/Lyn/Akt was identified in F/P-expressing 
cells, which can be disrupted by double inhibition of JAK2 
and Lyn, leading to significant suppression of proliferation 
in these cells. These results provide the feasibility of 
targeting both JAK2 and Lyn in treatment of F/P-positive 
CEL with imatinib-intolerance or IR, and also offer a new 
insight into the mechanism of F/P-driven CEL.
Lyn kinase has been implied as important actor for 
eosinophil proliferation and function in response to IL-5-
stimulation [10, 22, 23], we evaluated whether Lyn kinase was 
activated by F/P oncoprotein in CEL. As expected, the results 
displayed that all the F/P-positive CEL patients expressed 
higher level of phospho-Lyn than other F/P-negative subjects. 
The phosphorylated Lyn (p-Lyn) was inhibited with the 
suppression of phosphorylated F/P (p-F/P) by imatinib in a 
dose- and time-depended manner. This result places Lyn in the 
downstream of F/P oncoprotein. F/P-transformed cells undergo 
cytokine-independent proliferation and delayed apoptosis, 
being ascribed to its activating a common set of downstream 
molecules including ERK1/2, STAT5 and PI3K [1, 24–26]. 
However, these intercellular molecules cannot take full 
responsibility for the oncogenic role of F/P in CEL [1, 25]. 
As it can be directly bound and activated by PDGFR, Lyn 
has been proposed as a key actor in leukemogenesis through 
the recruitment of divergent intracellular signaling pathways 
[27–29]. Our results showed that Lyn inhibitor can 
dramatically reverse the function of F/P fusion gene 
promoting proliferation and anti-apoptosis of EOL-1 
cells, which indicated Lyn as an important player in the F/P-
positive CEL. 
Not BCR/ABL oncogene, but F/P oncogene is the 
co-stimulator for IL-5 to produce CEL [4]. Synergistic 
activation of cytokine-stimulated signaling pathways in 
the presence of other factors, has been observed in various 
cell types [30]. In eosinophils, priming with IL-5 family 
members is known to increase cellular responsiveness to 
chemoattractant and render a hypersensitive phenotype 
[8, 31]. Lyn is not only important for IL-5-induced 
signaling and cellular responses, but also as a key 
ingredient in the crosstalk between IL-5 and chemotactic 
factors [22]. If both cytokine IL-5 and F/P oncogene 
were introduced into the CD34+ cells, the overwhelming 
characteristics of F/P-positive CEL will be fully presented 
with end-organ impairment from eosinophil infiltration 
and activation [4]. The capacity of IL-5 to prime blood 
eosinophils hypersensitive to second stimulus has been 
associated with changes in intracellular signaling events. 
Several lines of evidences indicated that Lyn as one of 
the key players in the hyperactive phenotype of IL-5 
primed blood eosinophils [22, 32]. Our study showed 
that IL-5 can induce distinct augment of p-Lyn in F/P-
expressing eosinophil cells, which was partially prevented 
by pre-incubation with specific F/P inhibitor, imatinib. 
These results suggested the coordinated activation 
on Lyn signaling pathway from F/P oncoprotein with 
IL-5 cytokine. Additionally, there were no significant 
differences neither in the levels of p-F/P nor IL-5RA 
activation after IL-5 stimulation, which showed no direct 
evidence for trans-activation between IL-5RA and F/P 
molecule themselves [Data no shown]. Neither was there 
any hyperactivation of STAT5 or ERK by F/P cooperation 
with IL-5 [Data no shown]. 
Clinically, the CEL patients carrying F/P oncogene 
have a serious and extensive end-organ impairment 
resulting from the eosinophil infiltration and subsequent 
fibrosis [2]. Mostly, the eosinophils-related heart damage 
become the primary cause of morbidity and mortality 
in F/P-positive CEL [17]. MBP, one of the most potent 
eosinophilic granule proteins, is the major causes leading 
to severe target-organ damage [33]. 
Our data showed that MBP release was reduced 
with Lyn inhibition in EOL-1 cells. Lyn oncoprotein can 
promote induction of myeloproliferative neoplasm with 
myelofibrosis [34, 35]. Although the molecular mechanism 
was not yet clear, the results indicated that Lyn inhibition 
may become another possible strategy on blocking F/P-
induced eosinophil activation and thus eosinophil-related 
end-organ damage.
PI3K/Akt pathway was correlated with direct 
degranulation and superoxide production in the effect 
of IL-5 and F/P on blood eosinophils [20, 36], we were 
inspired to probe whether PI3K/Akt kinase can be 
activated by Lyn, conducting F/P-positive eosinophil 
invasion. As expected, our data showed that the 
phosphorylation level of PI3K and Akt proteins was 
strikingly decreased with Lyn inhibition in EOL-1 cells, 
which shed light on the F/P-induced end-organ eosinophil 
infiltration being through Lyn/PI3K/Akt pathway. STATs 
or ERK molecules are another important downstream 
effectors of IL-5 signal pathway during eosinophil 
development. However, our findings showed no enhanced 
activation of Stats or ERKs in F/P-positive CEL cells upon 
IL-5 stimulation. Thus, it is presumable that the synergism 
of F/P and IL-5 promotes aggressive eosinophil infiltration 
and activation by converging into intracellular Lyn/PI3K/
Akt pathway differing from those in normal eosinophil 
biological function.
Clinically, some F/P-positive CEL patients were 
sensitive to anti-IL-5 treatment albeit the serum IL-5 
concentrations of them were within the normal range. It 
supposed that happen via direct or an assumed activation 
role on IL-5R in F/P-expressing cells [4, 6]. Therefore, 
we investigated whether Lyn can be associated with 
IL-5RA and induce a presumed IL-5R activation of the 
F/P-expressing cells. The results showed that Lyn can 
physically associate with the IL-5RA in EOL-1 cells. 
Further study displayed that IL-5 cannot stimulate 
discernible IL-5RA activation when only IL-5RA was 
introduced into the CD34+ cells. However, the co-
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expression of FIP1L1-PDGFRA with IL-5R induced a 
prominent tyrosine phosphorylation of IL-5RA and Lyn, 
which was stronger upon IL-5 stimulation. 
Membrane targeting is known to be critical for 
controlling Lyn activity [37]. F/P-triggered signal cascade 
may lead to the recruitment of Lyn into membrane 
domains, and increase the basal activity of Lyn, which 
binds with specific IL-5R subunit, and thereby activate 
and amplify IL-5RA-related pathway. 
The processes by which Lyn contributes to the 
crosstalk between IL-5 and F/P- signal are not fully 
understood. JAK2 kinase is recognized as the primary 
initiator of IL-5R signaling, whereas Lyn has been 
implicated as a key ancillary kinase [38]. JAK2 was 
the downstream of F/P oncoprotein and enforced JAK2 
activation upon IL-5 stimulation was also verified in F/P-
related pathway [15]. It motivated our interest to explore 
whether Lyn could bind with JAK2 in F/P-positive 
EOL-1 cells. The other evidence supporting our study 
is that the fact about Lyn SH2 domain can direct bind 
to tyrosine-phosphorylated JAK2 [39]. JAK2 inhibition 
can inactivate Lyn kinase in BCR/ABL-induced Chronic 
Myeloid Leukemia (CML) [40, 41]. As expected, our 
study showed that Lyn protein can be detected in the anti-
JAK2 immunoprecipitation complexes, besides it occurred 
in the anti-F/P-immunoprecipitation complexes in F/P-
transfected 32D cells. These results revealed that Lyn is 
associated with JAK2 molecule in F/P-activated signal 
cascade. 
It was well-established that oncoproteins like BCR-
ABL, as well as PDGFR is combined to Src family and its 
downstream molecules [42, 43]. Therefore, we detected 
whether the signaling network including JAK2, Lyn, Akt 
and F/P exists in the F/P-expressing cells. The gel filtration 
experiments in Figure 6 support this hypothesis of F/P/
JAK2/Lyn/Akt complex in F/P(+) 32D cells and EOL-1 
cells.
F/P-positive cells are sensitive to imatinib in vitro 
and vivo. But imatinib resistance will eventually occur 
after long-time treatment for F/P-positive CEL, and 
imatinib has a possible cardio toxicity [14]. Moreover, 
the limited clinical activity of other TKIs highlights the 
need to develop new alternative strategy for blocking the 
growth of neoplastic eosinophils [44].
Recent reports show that dasatinib, a double inhibitor 
for Lyn and PDGFRA kinase, have the same or even more 
effectiveness than imatinib in F/P-positive CEL [14, 45–47]. 
Therefore, the F/P-positive cells were treated with the 
combination of low-dose JAK2 inhibitor and Lyn inhibitor, 
the cell proliferation was expectantly inhibited. The 
network complex of F/P/JAK2/Lyn/Akt was remarkably 
interrupted. Although the underlying mechanism is still 
unclear, we emphasize that the demolition of F/P/JAK2/
Lyn/PI3K complex do result from the inhibition of Lyn 
kinase and the rapid reduction of JAK2 protein levels. We 
propose a schematic diagram depicting Lyn activation of 
F/P-induced pathways to stimulate eosinophils proliferation 
and activation (Figure 7). 
In summary, we reveals that Lyn was activated 
by F/P oncoprotein. Moreover, the results feature Lyn 
as a significant participator for the pathogenesis of F/P-
positive CEL. Lyn is also critical for the enhanced release 
of MBP in F/P-induced eosinophils upon IL-5 stimulation. 
More importantly, this study underscores that Lyn maybe 
stimulates the hyperactive phenotype of F/P-positive cells 
in response to IL-5 stimulation, by associating with IL-
5RA and subsequently priming its signaling pathway, 
which in turn contribute to the increased proliferation 
and infiltration capacity of F/P-positive eosinophils. The 
identification of F/P/JAK2/Lyn/Akt complex emboldens 
us to hypothesize that Lyn may act as a signaling node, 
converging the F/P and IL-5 signals, which subsequently 
initiates and spreads multiple output signals such as MEK/
ERK and PI3K/Akt pathway [25]. Collectively, this study 
Figure 7: FIP1L1/PDGFRA in conjunction with IL-5 promote eosinophil proliferation and excessive activation. 
Systemic or local (paracrine or autocrine) IL-5 effects and indirectly through a putative up-regulation effect on IL-5RA signal pathway 
facilitation its intracellular signaling in F/P(+) cells. Lyn kinase was activated by F/P, and then associated with and phosphorylated IL-5RA, 
ease and amplify IL-5RA signal pathway.
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suggests that Lyn may be a potential therapeutic target for 
F/P-positive CEL patients with imatinib intolerance or 
resistance. These study disclose the molecular mechanisms 
of the crosstalk between oncogene and cytokine, which 
represents a model to study cellular integration of 
biochemical signals in cancer, being responsible for 
crucial aspects of cancer biology. 
MATERIALS AND METHODS
The present study protocol was approved by the 
ethical committee at Xiangya Hospital of Central South 
University, Changsha, China.
Patient samples
A total of 28 patients, including 23 cases of 
HES, five of reactive eosinophilia (R.E., two of which 
were eosinophilic gastroenteritis and three were 
ancylostomiasis) and five healthy volunteers, were 
included in this study. Karyotype analysis was normal. 
No abnormal chromosomes, including those of PDGFRB, 
FGFR1 and JAK2, were detected in any of the cases. The 
23 HES patients met all the criteria for the diagnosis of 
HES, as proposed by Chusid [48]. Nested RT-PCR and 
fluorescence in situ hybridization (FISH) analyses were 
performed on all samples, and the F/P fusion gene was 
detected in the 11 HES/CEL patients, but not in the other 
12 HES patients or other subjects. 10 of the 11 F/P(+) 
CEL cases had organ involvement (three of which had 
one impaired organ and seven had at least two impaired 
organs). The concentrations of serum IgE and IL-5 were 
normal in all 11 F/P(+) CEL patients. 
Cell culture
EOL-1 cells carried the WT F/P fusion oncogene 
(Braunschweig, Germany) [49]. Ba/F3 cells expressing 
T674I F/P resistant to imatinib (IR) have been described 
previously [1]. After obtaining blood from the above-
mentioned patients, polymorphonuclear leucocytes 
were separated by standard laboratory procedures 
[50]. Eosinophils were then separated by depletion 
of neutrophils with anti-CD16-coated magnetic 
microbeads using the magnetic cell separation system 
(MACS;Miltenyi Biotec GmbH, Bergisch- Gladbach, 
Germany). All these cell lines and primary cells were 
maintained in RPMI-1640 medium supplemented with 
10% fetal bovine serum (FBS) (Hyclone, USA) at 37°C 
in a humidified atmosphere of 5% CO2. IL-3-dependent 
32D cells were maintained in RPMI 1640 medium 
supplemented with 10% fetal calf serum(FCS) and 10% 
WEHI-3 conditioned medium as a source of IL-3 [51]. 
MACS immunomagnetic cell separation (Miltenyi 
Biotech, Auburn, CA) using a hapten-conjugated antibody 
against CD34, which was coupled to beads, was used to 
isolate CD34+ cells. CD34+ cells were cultured in Iscove’s 
modified Dulbecco’s medium (Life Technologies, Paisley, 
United Kingdom) supplemented with 8% FCS, 50 Amol/L 
of h-mercaptoethanol, 10 units/mL of penicillin, 10 Ag/mL 
of streptomycin, and 2 mmol/L of glutamine at a density 
of 0.3 × 106 cells/mL. 
Stimulation of cells with IL-5
EOL-1 or PC were preincubated with or without 
imatinib (10 nM) for 4 h and stimulated with IL-5 (5 ng/mL 
at 37°C for 0 to 5 min). The phosphorylation level of Lyn 
was detected by Western blotting at the time points of 0, 2 
and 5 min after IL-5 stimulation. 
Construction of lentiviral vectors
The shRNA sequence targeting Lyn and 
scrambled control shRNA sequence were designed 
and synthesized (GenScript, USA). The sequence 
information is listed below in detail: Lyn siRNA1: 
5′-AGAUUGGAGAAGGCUUGUAUU-3′; 5′-AAUAC 
AAGCCUUCUCCAAUCU-3′; Lyn siRNA2: 5′-CCAUC 
ACUGGUUGCACUUAUU-3′; 5′-AUAAGUGCAACCA 
GUGAUGG-3′; Lyn siRNA3: 5′-AGUAUUCUGUACUC 
UUAGAUU-3′; 5′-AUCUAAGAGUACAGAAUACU-3′. 
Scrambled control shRNA sequence: 5′-UUGUACCUA 
AUUUCGUCCCAC-3′; 5′-UGGGACGAAAUUAGGU 
ACAA-3′. Lentiviral DNA constructs were used co 
expressing enhanced green fluorescent protein (eGFP) and 
either FIP1L1-PDGFRA, fusing the NH2-terminal 233 
amino acids of FIP1L1 to the COOH-terminal 523 amino 
acids of PDGFRA [11], or/and IL-5RA [52]. Lentiviral 
vectors were packaged in T293 cells using reagent of the 
lipofectamine and plusTM, according to the manufacturers′ 
instructions (invitrogen, USA). 
Infection of cells with the lentiviral virus
Cells were cultured in the medium as above 
described. An appropriated amount of virus was diluted 
into the corresponding culture medium (containing 8 μg/
ml of polybrene) . Different types of recombinant viral 
supernatant and control viral supernatant were added 
separately. Then, the old medium was exchanged for the 
medium containing the virus, and the cells were incubated 
overnight. The following day, the medium containing 
the virus was removed and replaced with fresh culture 
medium. Transduced cells were selected using puromycin 
or blasticidin. Western blotting were executed for detecting 
the knockdown efficacy of Lyn protein for different Lyn 
shRNAs in EOL-1 cells. Lyn siRNA1 was selected for the 
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following experiments because of > 95% inhibitory rate 
for Lyn protein (Supplementary Figure S1). Transduction 
efficacy of F/P or/and IL-5RA into the cells was proved > 
90% (Supplementary Figure S2).
Colony formation assay
EOL-1, IR or PC cells were treated with different 
doses of PP2 or Lyn siRNA. After 72 hr, cells were seeded 
in triplicate into 35-mm dishes containing agarose and 
RPMI 1640. The plates were incubated at 37°C, in 5% 
CO2, for 2 weeks. Colonies (cell numbers ≥ 50 = colony) 
were counted and photographed. The inhibition rate was 
calculated as follows: Colony inhibition rate (%) = (1 
-Average colony number in treated group/Average colony 
number in blank control) ×100%.
Apoptosis assay 
Apoptosis was measured by Annexin-V-FLUOS 
and propidium iodide (PI) double staining, according 
to the manufacturers′ instructions (BD Biosciences 
Pharmingen, USA) and analyzed with a FACScalibur flow 
cytometer and CellQuestPro software (BD Biosciences). 
Morphological identification of apoptotic cells was refer 
to the method of Nicolatti et al. [53]. Briefly, EOL-1, 
IR or PC cells were cultured and treated with different 
concentrations of Lyn inhibitor (PP2) or knockdown 
with Lyn siRNA as described above. After the end of 
incubation, cell were collected, washed, and stained by 
acridine orange/ethidium bromide (AO/EB) or incubated 
with Annexin-V and then propidium iodide for flow 
cytometric analysis.
Eosinophil migration assay
Migration properties of EOL-1 and IR cells were 
analyzed in a 48-well microchamber (Neuroprobe, USA), 
in which the lower wells were filled with 28 μL of buffer 
alone or buffer containing 5 ng/mL IL-5. A fibronectin-
coated polyvinylpyrrolidone-free filter (Neuroprobe) 
with 5 μm pores was placed over the lower wells and 
50 μL of EOL-1 and IR cells at 4 × 106 cells/mL was 
added to the upper wells. The chamber was incubated for 
2 h at 37°C in a CO2 incubator. After the polycarbonate 
filter was removed and cells adhering to the upper 
surface were wiped off using a filter wiper. The filter 
was dried, fixed, and stained with Diff-Quick reagent 
(Baxter Diagnostics, USA). The cells in two randomly 
selected fields per well were counted using the Axiovert 
25 microscope (Carl Zeiss, Germany). Each experiment 
included six replicate measurements. The chemotactic 
index (CI) was calculated as the number of cells that 
migrated in experimental wells compared to those in 
control wells (was set at 100%). 
In vitro kinase assays
EOL-1 cells were starved overnight and left 
unstimulated (−) or stimulated with 5 ng/mL of IL-5 for 
5 minutes at 37°C before solubilization. For the IL-5R 
kinase assay, Cell lysates were immunoprecipitated with 
anti-IL-5R antibodies. After extensive washing, IL-5R 
immunoprecipitates were incubated with [γ −32P]ATP 
(15 Ci) for 30 min at room temperature in reaction buffer 
(20 mM HEPES [pH 7.6], 5 mM MnCl2, 100 mM NaCl, 
0.5 mM dithiothreitol, 1 mM Na3VO4, 5 mM MgCl2, 20 M 
cold ATP, 10 g of aprotinin/mL, 10g of leupeptin/mL). 
The reaction was stopped by adding 10 mM EDTA. 
The reaction mixture was resolved by SDS-PAGE and 
subsequently subjected to autoradiography. In CD34+ 
cells, the IL-5R was transiently co-expressed with 
FIP1L1-PDGFRA as indicated. Transfected cells were 
either stimulated with 5 ng/mL of IL-5 for 5 minutes 
or left unstimulated, as indicated (IL-5 st. + or −, 
respectively).Cells were lysed and immunoprecipitated 
with anti-IL-5Rα. Immunoprecipitates were analyzed 
by anti-phosphotyrosine (αPY) Immunoblotting 
followed by reprobing with anti-IL-5R, as indicated. 
A coimmunoprecipitated phosphotyrosyl protein that 
corresponds in size to Lyn is indicated with an asterisk. IL-
5R was immunoprecipitated with anti-IL-5R and subjected 
to an vitro kinase assay as Duan et al. described [54]. 
Immunoprecipitation and immunoblotting
For immunoprecipitation, the cell lysates were 
incubated on ice with anti-Lyn, anti-PDGFRA anti-JAK2 
or anti-IL-5RA antibody (1:100-1:1000 dilutions; Santa 
Cruz Biotechnology, USA) for 2 h. The immune complexes 
were collected following incubating with protein A-agarose 
(Roche, USA) at 4°C for 1 h. The beads were then washed 
three times with washing buffer and boiled for 5 min in 
SDS-PAGE sample buffer. The solubilized proteins were 
separated by SDS-PAGE, transferred to a nitrocellulose 
membrane (Amersham Biosciences, Sweden), and detected 
by immunoblotting against antiphosphotyrosine monoclonal 
antibody, 4G10 (αPY) or Western blotting was performed 
as described previously [15]. Blots were probed with the 
primary antibodies against phospho-Lyn (Y396) (p-Lyn), 
Lyn, phospho-p85a (PI3K)/(Tyr467)(p-p85a), p85a, 
phospho-Akt1 (Thr308/Ser473)(p-Akt1) and Akt1 (Santa 
Cruz Biotechnology, USA), phospho-Stat5(Tyr 694), and 
Stat5 (Invitrogen, USA), phospho-MAPK p44/42(Thr 
202/Tyr 204), MAPK, phospho-JAK2 (Tyr1007/1008)
(p-JAK2), JAK2 and β-actin (Cell Signaling Technology, 
USA) followed by incubation with the secondary antibodies 
were used peroxidase-conjugated goat antimouse IgG or 
goat anti-rabbit IgG (Jackson ImmunoResearch Inc., USA) 
and enhanced chemiluminescent substrate. Densitometry 
analysis was performed on exposed films using Quantity 
One v4.62 software (Bio-Rad, USA).
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Gel filtration column chromatography
The protein separation column selected for this 
purpose was 50 cm length × 0.7 cm diameter (Econo 
column, Bio-Rad, Hercules, CA), and the column material 
selected for this purpose was Superose 6 prep grade gel 
filtration (Amersham-Biosciences, part of GE Healthcare, 
Piscataway, NJ), which can achieve high-resolution 
separations across an exceptionally broad molecular weight 
range. The bed volume of the column was 17.5 mL, and 
the void volume was 6.0 mL. The composition of the 
elution buffer was 30 mM HEPES (pH 7.4) containing 
150 mM NaCl, 10% glycerol, and 0.5% NP-40. Elution 
rate was 4.56 mL/h. The column was standardized with 
the mixture of protein markers containing keyhole limpet 
hemocyanin (KLH; MW 8.5 million Da), blue dextran (2 
million Da), β-amylase (200 kDa), BSA (66 kDa), and 
cytochrome C (12.4 kDa). The fractions were collected in 
500 µL microfuge tubes in a fraction collector. The elution 
of the markers detected in 280 nm was plotted against the 
log of the molecular weight of the standard proteins. From 
this standard elution pattern, the size of the F/P protein 
network was estimated to be between 2 and 6 million. In a 
preequilibrated column, we loaded 150 µL (~3 mg) protein 
onto the column, and the proteins were separated into 
40 tubes, each containing approximately 500 µL column 
eluent. All the column fractions were stored at −20°C. From 
each column fraction, 25 µL was taken for analysis by 
Western blotting with various antibodies. Elution analysis 
of fractions 8 to 24 were performed in 3 premade gradient 
SDS-PAGE gels (4%–20%). The proteins were transferred 
to PVDF membranes. The membranes were blocked with 
BSA for detection of p-Tyr, and for detection of F/P and 
other proteins, blocking was carried out with 5% milk, and 
Western blotting was carried out as described earlier. 
Fluid-phase measurements
MBP values were determined using a double 
antibody competitive radioimmunoassay [55]. The 
sensitivities for MBP were less than 1 ng/ml and 2 ng/ml, 
respectively. The result was adjusted for dilution.
Statistical analysis
Data are presented as mean ± standard deviation 
(SD). Data were compared using the two-way analysis 
of variance (ANOVA) test or independent sample t test. 
P values less than 0.05 was considered statistically 
significant and were derived from 2-tailed statistical test. 
All statistical treatment was performed using SPSS 13.0 
software.
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